Temple Times Online Edition
    MAY 18, 2006
NewsEventsArchivesPhotosStaffLinksTemple Home

Bio grad students present research at conference

Four biology graduate students who work in the lab of professor George P. Tuszynski in the newly formed neuroscience department presented their research at the American Association for Cancer Research meeting in Washington, D.C., April 1–5.

The students shared work they had done on how angiocidin, an anti-angiogenic and anti-tumor protein discovered in Tuszynski’s lab, functions to stop cancer growth.

“I am extremely proud of the accomplishments of these students at the AACR meeting,” Tuszynski said. “Their hard work, and the recognition it received from cancer researchers across the spectrum, reflects well on not only on my lab and the departments of biology and neuroscience, but Temple University as well. I am thankful for Temple’s commitment to biomedical research for both faculty and students.

Each student was awarded the newly developed travel award provided by the College of Science and Technology to support graduate research.”

Darryl Z. L’Heureux’s paper, describing how angiocidin disrupts the cell cytoskeleton, the major scaffold of the cell, and how this disrupting activity contributes to the anti-angiogenic activity of angiocidin, won the prestigious AACR-AstraZeneca Scholar-in-Training Award, which includes a stipend of $1,000. He was among 43 students whose papers were chosen for this award from the more than 16,000 papers presented at the meeting.

Anita Gaurnier was chosen to give an oral presentation at a prestigious mini-symposium organized by Robert Kerbel, a leading cancer therapy expert. She presented her work on the role of angiocidin in the modulation of immune function.

Yamini Sabherwal presented her work on the binding of angiocidin to tumor and endothelial cells, in which she identified a cell surface adhesion receptor for angiocidin.

Finally, Xiao Yang presented work in which she has been able to modulate the expression of angiocidin in cells using short inhibitory RNA. Tuszynski said this technology holds promise in further defining the role of angiocidin in tumor progression.

- Preston M. Moretz